ADVI Health’s expertise was recently featured in a STAT article, analyzing the disparities of access to CAR-T therapies in Medicare beneficiaries. Our Strategic Analytics, Value and Economics (SAVEs) team developed a study to examine real-world patterns for disparities in CAR-T immunotherapy access, resulting in a concerning outcome.

In the article, “CAR-T Crossroads: Policy, Politics, and Patients,” ADVI Health’s CEO, Marc Samuels, shares his insights on ADVI’s role representing cell and gene therapy organizations, and assisting in the launch of 90 percent of CAR-T therapies.

Read more in STAT.